Bruserud O, Hamann W, Pawelec G
Second Department of Internal Medicine, Tubingen University Medical Clinic, FRG.
Eur J Haematol. 1995 Feb;54(2):106-10. doi: 10.1111/j.1600-0609.1995.tb01776.x.
CD4+ and CD8+ TCR alpha beta+ T-cell clones were derived from 4 leukaemia patients early (4-6 weeks) after allogeneic bone marrow transplantation. Leukemia inhibitory factor (LIF) secretion in response to the activation signal accessory cells (AC) + phytohaemagglutinin (PHA) was investigated for each individual clone. Only a minority of CD4+ TCR alpha beta+ T-cell clones secreted LIF in response to AC + PHA, whereas most T-cell clones were capable of LIF secretion when exogenous interleukin 2 was added together with AC + PHA. LIF secretion could also be demonstrated for CD8+ TCR alpha beta+ posttransplant T-cell clones. Thus, posttransplant CD4+ and CD8+ TCR alpha beta+ clonogenic T-cells are capable of LIF secretion, and LIF secretion may be a T-cell effector mechanism in graft versus host disease, graft versus leukaemia effects or posttransplant haematopoietic reconstitution.
CD4+和CD8+ TCRαβ+ T细胞克隆源自4例异基因骨髓移植后早期（4 - 6周）的白血病患者。针对每个单独的克隆，研究了其对激活信号辅助细胞（AC）+植物血凝素（PHA）的反应中白血病抑制因子（LIF）的分泌情况。只有少数CD4+ TCRαβ+ T细胞克隆在AC + PHA刺激下分泌LIF，而当外源性白细胞介素2与AC + PHA一起添加时，大多数T细胞克隆能够分泌LIF。移植后CD8+ TCRαβ+ T细胞克隆也可检测到LIF分泌。因此，移植后CD4+和CD8+ TCRαβ+克隆形成性T细胞能够分泌LIF，LIF分泌可能是移植物抗宿主病、移植物抗白血病效应或移植后造血重建中的一种T细胞效应机制。
